- USPTO issued Notice of Allowance for U.S. Patent Application No. 17/590,496
- Patent covers weight-banded dosing of trofinetide for Rett syndrome
- Expected to extend U.S. patent protection to March 28, 2041
- Extends prior method-of-use patent expiring July 2036 by nearly five years
- Patent includes six months of pediatric exclusivity
- trofinetide is marketed as DAYBUE and DAYBUE STIX in the U.S.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card